James Dentzer, Curis CEO
Curis shrinks headcount by 30% as execs place bigger hopes on blood cancer drug
Now that it’s gotten both clinical holds lifted for the blood cancer drug emavusertib, Curis is ready to move full speed ahead.
But first, it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
